Pacira BioSciences Partners with AmacaThera
In an exciting development for pain management, Pacira BioSciences, Inc. (Nasdaq: PCRX), recognized for its commitment to transforming patient care through innovative, non-opioid pain therapies, is partnering with AmacaThera. This collaboration centers around an exclusive worldwide license and agreement for the development of AMT-143, a groundbreaking long-acting formulation of the non-opioid analgesic ropivacaine. This agreement reinforces Pacira’s focus on providing effective postsurgical pain control.
Enhancing Pain Management with AMT-143
The introduction of AMT-143 represents a significant step in expanding Pacira's product pipeline. Frank D. Lee, the CEO of Pacira, emphasizes that this novel formulation aligns perfectly with the company’s strategy to lead in opioid-sparing pain management. He expressed confidence in the asset's potential to enhance their existing offerings while addressing the unmet demand for safe, longer-acting pain treatment options for both patients and healthcare providers.
AMT-143 is designed to provide sustained pain relief, a key requirement for patients undergoing surgery. The formulation is administered at the time of surgery and was shown in Phase 1 trials to release ropivacaine consistently over 14 days, promising significant improvement in pain control experiences.
Collaboration and Financial Aspects
The collaboration between Pacira and AmacaThera involves a comprehensive agreement where Pacira will finance clinical development through to commercial launch. The two companies will work closely on Phase 2 clinical trials, with AmacaThera set to receive an initial payment of $5 million. Additional milestone payments and a tiered royalty based on future sales could significantly benefit both companies.
About AMT-143
AMT-143 leverages AmacaThera’s advanced hydrogel-based drug delivery system, providing a highly effective and minimally invasive solution for postoperative pain management. The hydrogel is designed to gel upon reaching body temperature, forming a depot that releases medication steadily, thereby reducing systemic side effects.
Current Portfolio of Pacira
Pacira has already established a strong foothold in the market with the success of three commercial-stage non-opioid treatments: EXPAREL, ZILRETTA, and iovera°. EXPAREL is specifically designed for local analgesia, approved for various surgical procedures, while ZILRETTA targets osteoarthritis knee pain. The innovative iovera° device offers immediate, drug-free pain relief, showcasing Pacira's commitment to non-opioid solutions.
Looking Ahead: Phase 2 Program and Market Impact
The anticipated Phase 2 program for AMT-143 is expected to start in the near future, aiming to expand the range of effective non-opioid pain options available in the market. There is an increasing recognition of the need for alternative pain management approaches that not only alleviate discomfort but also minimize the risks associated with opioid use.
As Pacira continues to deepen its focus on innovative products that meet evolving patient needs, the partnership with AmacaThera could strategically position them to capture a larger market share. The combination of AMT-143's potential with their existing treatments might enhance cash flow and earnings significantly as these new products come to fruition.
Frequently Asked Questions
What is the purpose of the agreement between Pacira and AmacaThera?
The agreement focuses on the development and commercialization of AMT-143, a novel long-acting analgesic for effective postsurgical pain control.
How does AMT-143 work to alleviate pain?
AMT-143 utilizes a hydrogel-based delivery system that provides a sustained release of ropivacaine, which helps manage pain over a prolonged period after surgery.
What are the key products offered by Pacira BioSciences?
Pacira’s key products include EXPAREL, ZILRETTA, and iovera°, all designed to provide non-opioid pain relief and improve patient experiences.
When is the Phase 2 program for AMT-143 expected to start?
The Phase 2 program for AMT-143 is anticipated to begin in the near future, showcasing Pacira's commitment to advanced pain management solutions.
How does this collaboration fit into Pacira’s broader business strategy?
The collaboration supports Pacira’s 5x30 growth strategy, prioritizing innovative and derisked opportunities that enhance their product offerings in pain management.
